Analyst Price Targets — EXEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:24 am | — | Barclays | $45.00 | $44.89 | TheFly | Exelixis price target raised to $45 from $44 at Barclays |
| February 12, 2026 11:05 am | — | H.C. Wainwright | $54.00 | $42.94 | TheFly | Exelixis price target raised to $54 from $52 at H.C. Wainwright |
| February 11, 2026 12:11 pm | — | Stifel Nicolaus | $44.00 | $42.98 | TheFly | Exelixis price target raised to $44 from $43 at Stifel |
| February 4, 2026 10:46 am | Etzer Darout | Barclays | $44.00 | $42.59 | TheFly | Exelixis price target raised to $44 from $41 at Barclays |
| February 2, 2026 1:07 pm | Sean Laaman | Morgan Stanley | $49.00 | $41.29 | TheFly | Exelixis price target raised to $49 from $48 at Morgan Stanley |
| January 14, 2026 1:59 pm | — | Truist Financial | $51.00 | $44.65 | TheFly | Exelixis price target raised to $51 from $49 at Truist |
| January 8, 2026 2:30 pm | Robert Burns | H.C. Wainwright | $52.00 | $44.79 | TheFly | Exelixis price target raised to $52 from $49 at H.C. Wainwright |
| January 8, 2026 11:21 am | — | Morgan Stanley | $48.00 | $46.19 | TheFly | Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley |
| January 5, 2026 11:11 am | — | UBS | $41.00 | $43.58 | StreetInsider | BofA Securities Downgrades Exelixis (EXEL) to Underperform |
| November 5, 2025 4:33 pm | Robert Burns | H.C. Wainwright | $49.00 | $40.52 | TheFly | Exelixis price target raised to $49 from $46 at H.C. Wainwright |
Latest News for EXEL
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Financial Group LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 25.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,956 shares of the biotechnology company's stock after acquiring an additional 17,615 shares during
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EXEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.